Bsw Wealth Partners Crispr Therapeutics Ag Transaction History

Bsw Wealth Partners

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$43.47 - $67.77 $2,216 - $3,456	-51 Reduced 0.84%	6,022 $338,000
Q1 2023 May 15, 2023	BUY	$41.0 - $56.12 $248,993 - $340,816	6,073 New	6,073 $274,000
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $183 - $251	-3 Reduced 0.06%	4,910 $321,000
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $39,641 - $67,702	917 Added 22.95%	4,913 $299,000
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $212,547 - $316,643	3,996 New	3,996 $251,000
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $160,561 - $228,224	-1,457 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $146,923 - $235,873	1,457 New	1,457 $236,000
Q4 2019 Feb 18, 2020	SELL	$36.68 - $73.13 $30,811 - $61,429	-840 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$40.99 - $52.56 $819 - $1,051	20 Added 2.44%	840 $34,000
Q2 2019 Aug 13, 2019	BUY	$35.45 - $48.2 $29,069 - $39,524	820 New	820 $39,000

486

57.9M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.39B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Bsw Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Bsw Wealth Partners with notifications on news.